PF06447475 is a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD) by genome-wide association studies (GWAS). The most common LRRK2 mutation, G2019S, which is relatively rare in the total population, gives rise to increased kinase activity. As such, LRRK2 kinase inhibitors are potentially useful in the treatment of PD.
中文别名 | PF-06447475(MSDS,1527473-33-1); PF06447475; PF-06447475; PF 06447475; PF6447475; PF-6447475; PF 6447475. |
英文别名 | PF-06447475;PF-06447475: |
CAS号 | 1527473-33-1 |
SMILES | c1cc(cc(c1)c2c[nH]c3c2c(ncn3)N4CCOCC4)C#N |
Inchi | InChI=1S/C17H15N5O/c18-9-12-2-1-3-13(8-12)14-10-19-16-15(14)17(21-11-20-16)22-4-6-23-7-5-22/h1-3,8,10-11H,4-7H2,(H,19,20,21) |
InchiKey | BHTWDJBVZQBRKP-UHFFFAOYSA-N |
分子式 Formula | C17H15N5O |
分子量 Molecular Weight | 305.33 |
Polarizability极化度 | 33.8±0.5 10-24cm3 |
密度 Density | 1.4±0.1 g/cm3 |
储藏条件 Storage conditions | 粉末Powder: -20℃ 3 years年 4℃ 2 years年 / In solvent溶液中:-80℃ 6 months月 -20℃ 1 month月 |